Key Takeaways:
- The FDA's clearance of an at-home, prescription-based HPV test signals a broader regulatory acceptance of decentralized diagnostic models, impacting how providers and labs manage patient screening.
- The direct-to-patient distribution model, covered by major insurers, opens a new revenue channel and expands the addressable market by targeting the estimated 60% of individuals who are unscreened or under-screened.
- Successful implementation at scale will depend on high-throughput laboratory automation, such as the BD COR™ System, to efficiently process an influx of self-collected samples and ensure reliable results.
The U.S. Food and Drug Administration has cleared an at-home self-collection kit for human papillomavirus (HPV) screening, a development that stands to alter the landscape for diagnostic companies, clinical laboratories, and healthcare providers. Waters Corporation announced on Wednesday that its Onclarity HPV Self-Collection Kit, used with the BD Onclarity HPV Assay, received clearance, allowing for prescription-based distribution directly to patients.
The move addresses a critical public health challenge and a significant untapped market: approximately 60% of cervical cancer cases occur in individuals who have not been adequately screened. By moving the point of sample collection into the home, the new model aims to overcome common barriers to screening, such as access to care, time constraints, and patient discomfort.
"U.S. FDA clearance of the Onclarity Self-Collection Kit for at-home use marks a meaningful step towards removing today's primary barriers to screening, and supporting more personalized care," says Jianqing Bennett, Senior Vice President of Waters Advanced Diagnostics at Waters Corporation.
For healthcare providers and systems, the operational shift could translate to greater efficiency. By empowering patients to complete screenings remotely, clinical resources can be reallocated from routine screening appointments to higher-value activities.
"When more patients are able to get screened, whether at home or in the clinic, clinicians have better information to identify risks earlier and intervene sooner," said Dr. Jeff Andrews, Vice President of Medical Affairs for Waters Advanced Diagnostics. "That allows us to spend less time trying to reach patients who have fallen behind on screening and more time focusing on prevention, follow-up care, and treatment for those who need it."
The logistical framework for the new system relies on a network of partnerships that Waters is currently building. The kit will be available by prescription in the coming months and is designed to be mailed to a patient's home. After self-collection, the sample is mailed to a laboratory for analysis. The process leverages the fully automated BD COR™ System, which uses robotics to prepare and analyze samples, a crucial technology for labs needing to manage the potential volume increase from at-home testing while maintaining quality control.
Results are delivered to the prescribing healthcare provider, who then manages patient follow-up. With coverage planned across private insurance, Medicaid, and Medicare, the financial infrastructure is being positioned to support broad adoption. This model requires tight integration between diagnostic manufacturers, distributors, healthcare prescribers, and clinical laboratories to ensure a seamless workflow from prescription to final report.
